Open-label, Single-arm, Multiple-dose Safety, Titration, and Pharmacokinetic Trial of Afrezza in Pediatric Patients Ages 4 to 17 Years With Type 1 Diabetes Mellitus
Phase of Trial: Phase I
Latest Information Update: 18 Mar 2016
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Adverse reactions
- Sponsors Sanofi
- 14 Mar 2016 Status changed from recruiting to suspended, according to ClinicalTrials.gov record.
- 07 Oct 2015 Planned End Date changed from 1 Jul 2017 to 1 Aug 2017, according to ClinicalTrials. gov record.
- 07 Oct 2015 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017, according to ClinicalTrials. gov record.